Wisam Naji, MD
Pulmonary Disease · Valencia, CANPI 1407119738
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,500 of the $8,622 with a category attached, or 87.0%. Intuitive Surgical accounts for 91.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $4,850 and has fallen 91.9% since, to $391 in 2025.
Across 17 payments — averaging $507.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Boehringer Ingelheim$484
- Abiomed$141
- Organon$20
- ERBE USA Inc$20
- Sobi, Inc$20
- plus $13 from 1 others
What the payments were for
- Travel & lodging$2092%
- Food & beverage$91311%
- Education$7,50087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $7,923 |
| Boehringer Ingelheim | 4 | $484 |
| Abiomed | 1 | $141 |
| Organon | 1 | $20 |
| ERBE USA Inc | 1 | $20 |
| Sobi, Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,821
- ION$3,000
- OFEV$251
How this compares
$8,622 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 396 | $346,607 |
| Spiriva RespimatTiotropium Bromide | 125 | $78,827 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 129 | $70,204 |
| Advair HfaFluticasone Propion/Salmeterol | 161 | $69,957 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $50,844 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 86 | $47,845 |
| Spiriva HandihalerTiotropium Bromide | 30 | $31,064 |
| DuleraMometasone/Formoterol | 38 | $15,183 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $14,365 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 89 | $14,325 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $13,924 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 24 | $12,179 |
| Wixela InhubFluticasone Propion/Salmeterol | 63 | $11,508 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 390 | $11,459 |
| BreynaBudesonide/Formoterol Fumarate | 30 | $6,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $484 | $132,309222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Valencia
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.